Biologic Drugs

Oct 23, 2017
By Pharmaceutical Technology Editors
The $72-million investment, part of a larger $850-million investment into its US operations, will allow the drugmaker to replace an outdated insulin vial-filling line and to upgrade technology at its Indianapolis manufacturing plant.
Oct 20, 2017
By Pharmaceutical Technology Editors
The companies aim to use CureVac’s proprietary messenger RNA technology to develop and commercialize up to five potential cancer vaccine products.
Oct 20, 2017
By Pharmaceutical Technology Editors
This approval marks the second gene therapy to be approved by FDA and the first to be approved for certain types of non-Hodgkin lymphoma.
Oct 16, 2017
By Pharmaceutical Technology Editors
The vaccine is a non-live, recombinant subunit vaccine that combines an antigen and an adjuvant system to trigger a targeted and long-lasting immune response to the shingle-causing virus.
Oct 16, 2017
By Pharmaceutical Technology Editors
Stelara (ustekinumab), already approved for treating adults, is now also approved for treating adolescents with moderate to severe plaque psoriasis.
Oct 14, 2017
By Pharmaceutical Technology Editors
Samsung BioLogics’ second facility adds 152,000 L of mAb drug substance capacity.
Oct 13, 2017
By Pharmaceutical Technology Editors
The committee has voted unanimously to approve Spark Therapeutics’ gene therapy candidate, Luxturna (voretigene neparvovec), for treating a genetically inherited blindness.
Oct 11, 2017
By Pharmaceutical Technology Editors
Johnson & Johnson’s Janssen Sciences Ireland UC will invest more than EUR 300 million (US$355 million) to expand manufacturing capacity for biologic medicines at its Ireland facility.
Oct 11, 2017
By Pharmaceutical Technology Editors
BARDA has entered a $12-million contract with biopharmaceutical firm Achaogen for the late-stage development of an antibiotic against resistant bacteria, and as a potential treatment for biowarfare agents.
Oct 11, 2017
By Pharmaceutical Technology Editors
AstraZeneca is seeking approval for its anti-cancer monoclonal antibody, Imfinzi, for treating non-small cell lung cancer in the European Union.
native1_300x100
lorem ipsum